Kikuchi-Fujimoto Disease

1. Disease Information

Overview. Kikuchi-Fujimoto disease (KFD), synonymously histiocytic necrotizing lymphadenitis (HNL), is a rare, benign, usually self-limiting cause of subacute regional (typically cervical) lymphadenopathy with fever. It was described independently in Japan in 1972 by Masahiro Kikuchi and by Yoshiro Fujimoto. Diagnosis is exclusively histopathological — the clinical and imaging picture is nonspecific and closely mimics both lymphoma and lupus lymphadenitis, so an excisional lymph-node biopsy is essential (PMC11592699, MDPI Diseases 2024; comprehensive review, PMID 37383134 / PMC10294163).

"A rare form of necrotizing lymphadenitis, is an uncommon, benign, self-limiting disorder of obscure etiology." — comprehensive review (PMID 37383134)

Key identifiers.

(Identifiers compiled from Orphanet/NORD/EBI-OLS listings — please re-verify MONDO/ICD mappings against the local sqlite:obo:mondo adapter before committing, per the NEC preflight in CLAUDE.md.)

Synonyms / alternative names: Kikuchi disease; Kikuchi-Fujimoto syndrome; histiocytic necrotizing lymphadenitis (HNL); necrotizing lymphadenitis; subacute necrotizing lymphadenitis.

Data provenance: Disease-level, aggregated from case series and reviews (not EHR/individual-patient registries). No dedicated large prospective registry exists.

2. Etiology

The cause is unknown. Two non-exclusive hypotheses dominate: (a) an infectious trigger (most often viral) and (b) an exaggerated, self-limited autoimmune/T-cell–mediated response in a genetically susceptible host — essentially a transient "SLE-like" reaction.

Infectious/viral hypothesis. Many agents have been associated (temporally, serologically, or by case report) but none proven causal: EBV, HSV, VZV, HHV-6/7/8, parvovirus B19, paramyxovirus, parainfluenza, rubella, CMV, and — more recently — SARS-CoV-2 infection and post-COVID-vaccination cases (PMC11592699). Support for a viral component comes from raised IFN-α and its downstream marker 2′,5′-oligoadenylate synthetase, plus tubuloreticular structures in the cytoplasm of stimulated lymphocytes/histiocytes/endothelium — an interferon-signature also seen in SLE (PMID 37383134).

"Increased levels of IFN-α and its stimulators including 2′,5′-oligoadenylate synthetase, and tubuloreticular structures in the cytoplasm of stimulated lymphocytes." — PMID 37383134

Autoimmune hypothesis. KFD is postulated to be "a self-limiting SLE-like autoimmune disorder caused by virus-infected transformed lymphocytes" triggering a cell-mediated response "to a variety of antigens in genetically susceptible people" (PMC11592699).

Genetic risk factors. No causal Mendelian gene. The principal susceptibility signal is HLA class II, notably HLA-DPA1 and HLA-DPB1 alleles that are far more common in East Asians than in Europeans. A Japanese case-control study (86 KFD patients vs 525 controls) found DPA1*01 and DPB1*0202 significantly over-represented in KFD; these alleles are common in Korea (~9.9%) and Japan (~4.5%) but rare in French (~0.4%) and Italian (~0.8%) populations — plausibly explaining the Asian predominance (summarized in PMC11592699). A 2023 report described familial KFD in HLA-partially-matched siblings both carrying DPB1*0202 (PMC10803893). RNA- and exome-sequencing efforts have begun to nominate additional candidate genes (ScienceDirect S0890850821000359).

Environmental / lifestyle risk factors: young age and Asian ancestry are the strongest demographic risks; female sex from the 30s onward. No confirmed occupational, toxic, dietary, or smoking association.

Protective factors: none established (genetic or environmental).

Gene–environment interaction (working model): an environmental antigen (virus) in a host carrying permissive HLA-DP alleles drives an over-exuberant CD8⁺ T-cell response that produces the necrotizing lesion, then self-terminates.

3. Phenotypes

For a KB entry, the core phenotype bundle (with suggested HPO terms and approximate frequencies from case series) is:

Characteristics. Onset is subacute over 1–4 weeks; symptom duration averages ~2–3 weeks but can persist — one Japanese cohort reported a mean symptomatic duration of 71.5 days (PMID 39961627 / PMC12129606). Severity is usually mild–moderate and self-limited; a minority have severe systemic/extranodal disease. Course is self-limited but occasionally recurrent (see §8, §11).

"Fever (55.2%) was the most common clinical manifestation. Leukopenia (49.3%) was the commonest reported laboratory abnormality." — cervical-KFD retrospective (n=134), PMC10446312

Quality-of-life impact: generally limited given self-resolution, but the diagnostic odyssey (fear of lymphoma), painful nodes, prolonged fever, and recurrence-related anxiety are the main burdens. No KFD-specific QoL instrument exists.

4. Genetic / Molecular Information

• Causal genes: none. KFD is not a Mendelian disorder.
• Susceptibility loci: HLA-DPA1 (HGNC:4938) and HLA-DPB1 (HGNC:4940); risk alleles DPA1*01, DPB1*0202 (PMC11592699; familial case PMC10803893). These are germline, common population variants (association, not pathogenic mutations) — not classifiable by ACMG as pathogenic.
• Somatic vs germline: the HLA association is germline; no recurrent somatic driver is described (KFD is non-neoplastic — clonality studies are typically negative, distinguishing it from lymphoma).
• Modifier genes / epigenetics / chromosomal abnormalities: none established. Karyotype and clonality are normal — an important negative used to exclude lymphoma.
• Emerging genomics: RNA-seq/exome studies are early-stage and nominate immune/interferon-pathway genes rather than a single culprit (ScienceDirect 2021).

Suggested gene descriptors (HGNC): hgnc:4938 (HLA-DPA1), hgnc:4940 (HLA-DPB1). Because casing in this repo is lowercase hgnc:.

5. Environmental Information

• Environmental/toxic/occupational factors: none confirmed.
• Lifestyle factors: none confirmed.
• Infectious agents (candidate triggers, unproven): EBV (NCBITaxon:10376), HSV (10298), VZV/HHV-3 (10335), HHV-6 (10368), HHV-8 (37296), parvovirus B19 (10798), CMV/HHV-5 (10359), paramyxoviruses, parainfluenza, rubella virus (11041), SARS-CoV-2 (2697049) — associations are temporal/serological; no organism has been consistently isolated or shown causal (PMC11592699; SARS-CoV-2-triggered case, PMC10077921).

6. Mechanism / Pathophysiology

Causal chain (best-supported hypothesis):

1. Trigger — a viral (or other) antigen in an HLA-DP–permissive host.
2. Interferon-driven activation — type I IFN (IFN-α) signature: elevated 2′,5′-oligoadenylate synthetase, tubuloreticular inclusions, and recruitment/activation of plasmacytoid dendritic cells (pDCs) (upstream) (PMID 37383134).
3. CD8⁺ cytotoxic T-cell response — an exaggerated T-cell–mediated immune response with marked CD8⁺ T-lymphocyte predominance.
4. Fas–Fas-ligand apoptosis — "apoptotic cell death induced by the Fas–Fas ligand system mediated by cytotoxic CD8+ cells is the principal mechanism of cellular destruction in KFD" (PMID 37383134). This produces the hallmark apoptotic karyorrhexis.
5. Histiocytic phagocytosis — CD68⁺/CD163⁺/MPO⁺ histiocytes (many crescentic/"C-shaped" nuclei) clear apoptotic debris, forming necrotic foci without neutrophils and without well-formed granulomas (downstream) (PMC11592699).
6. Self-limited resolution — the response terminates, node architecture recovers.

Cell types involved (suggested CL terms): - CD8⁺ cytotoxic T cell — CL:0000794 - Plasmacytoid dendritic cell — CL:0000784 (CD123⁺/CD303⁺; a defining infiltrate) - Myeloid/immature dendritic cell — CL:0000840 (immature) / CL:0000451 - Histiocyte / macrophage — CL:0000235 (CD68⁺, CD163⁺, MPO⁺, lysozyme⁺) - Immunoblast (large transformed lymphoid cell) — CL:0000653? (use B/T immunoblast as available)

Immunophenotype of the diagnostic lesional cells (Pileri/Facchetti-type analysis, PMID 19141377): the "plasmacytoid" mononuclear cells are two populations of immature dendritic cells — myeloid DCs (CD68⁺, CD1c/BDCA-1⁺, CD13/CD33⁺) and plasmacytoid DCs (CD303/BDCA-2⁺, CD123⁺), strongly MxA⁺ (IFN-α–inducible) and fascin-negative (immature).

"The morphologically distinctive mononuclear cells in lesional areas consisted of 2 populations of immature DCs: myeloid DCs …" — PMID 19141377

Suggested GO biological-process terms: - GO:0006915 apoptotic process (INCREASED) - GO:0097191 extrinsic apoptotic signaling pathway / GO:0036337 Fas signaling (INCREASED) - GO:0060337 type I interferon signaling pathway (INCREASED) - GO:0001913 T cell–mediated cytotoxicity (INCREASED) - GO:0006909 phagocytosis (INCREASED) - GO:0002456 T cell–mediated immunity (INCREASED)

Immune involvement: this is fundamentally an immune-mediated disease (cytotoxic T cell + interferon + dendritic-cell axis), sitting on a spectrum toward SLE — hence the overlapping interferon signature and the clinical progression of a subset to lupus. Molecular profiling beyond IHC (bulk transcriptomics/single-cell/proteomics) is sparse; no metabolomic or lipidomic signature is defined.

7. Anatomical Structures Affected

• Primary: lymph nodes, especially cervical (posterior triangle, levels II–V), usually unilateral (UBERON:0000029 lymph node; UBERON:0002429 cervical lymph node). ~85% cervical.
• Other nodal sites: axillary, supraclavicular, mesenteric, mediastinal; generalized lymphadenopathy in a minority.
• Extranodal / secondary (organ systems): skin (UBERON:0002097; 30–40%), spleen (UBERON:0002106, splenomegaly), liver (UBERON:0002107), bone marrow (UBERON:0002371, in HLH), and CNS (UBERON:0001017 — aseptic meningitis, meningoencephalitis, cerebellar ataxia, optic neuritis).
• Tissue/cell level: paracortical (T-zone) expansion with patchy necrosis; infiltrate of CD8⁺ T cells, immature dendritic cells, and histiocytes; B cells and plasma cells characteristically scarce (their presence suggests lupus instead).
• Subcellular (GO cellular component): cytoplasmic tubuloreticular structures (endoplasmic-reticulum–derived; GO:0005783 endoplasmic reticulum); nuclear fragmentation (karyorrhexis) of apoptotic bodies.
• Lateralization: predominantly unilateral cervical.

8. Temporal Development

• Onset: young adults (mean ~30 years); subacute over days–weeks. Pediatric cases occur.
• Course: self-limited, typically resolving in 1–4 months. Symptom duration is variable (mean ~71.5 days in one series; PMID 39961627).
• Histologic evolution: proliferative (early) → necrotizing (peak) → xanthomatous/foamy (resolving) phases — a temporal, not just categorical, sequence (PMC11592699). The necrotizing pattern correlates with larger nodes and longer symptom duration (PMID 39961627).
• Remission: usually spontaneous; corticosteroids hasten resolution in severe cases.
• Recurrence: reported ~3–23% in adults (up to ~42% in some pediatric series); often multiple episodes (44% of recurrers had ≥2). Recurrence flags a higher likelihood of underlying/evolving autoimmunity (see §11).

9. Inheritance and Population

• Epidemiology: rare; true incidence/prevalence undefined. Most reported cases are from East and Southeast Asia; uncommon in the US/Europe.
• Age: predominantly 20–40 years (mean ~29–30).
• Sex: historically described as female-predominant (older reports up to ~1:4 M:F), but recent large series show a near-equal or only mildly female-skewed ratio — one 112-patient Japanese cohort was 54.5% female, with male predominance up to age 20 and female predominance from the 30s onward (PMID 39961627 / PMC12129606).
• Inheritance pattern: not inherited in a Mendelian sense; multifactorial with an HLA-DP association and rare familial clustering (PMC10803893). No penetrance/expressivity/anticipation/mosaicism/founder/carrier-frequency parameters apply.
• Geographic distribution: endemic-appearing clustering in Asia, mirroring HLA-DPB1*0202/DPA1*01 allele frequencies.

10. Diagnostics

Definitive test: excisional lymph-node biopsy with histopathology (FNA is often nondiagnostic and risks missing lymphoma).

• Histopathology (diagnostic hallmarks): paracortical necrotizing foci with abundant apoptotic karyorrhexis, crescentic histiocytes, immunoblasts, and plasmacytoid dendritic cells; absence of neutrophils and plasma cells; no granulomas. Three patterns: proliferative (~77%), necrotizing (~22%), xanthomatous (~1%) (PMID 39961627).
• Immunohistochemistry: CD8⁺ T cells predominate (CD4:CD8 reversed); histiocytes CD68⁺/CD163⁺/MPO⁺/lysozyme⁺; CD123⁺ plasmacytoid DCs; scant CD20⁺ B cells; no clonal rearrangement (excludes lymphoma).
• Laboratory: leukopenia (commonest), atypical lymphocytes, elevated ESR/CRP, elevated LDH, mild transaminitis, anemia; ANA usually negative at baseline (positivity raises suspicion of SLE).
• Imaging (supportive, nonspecific): ultrasound — enlarged nodes with preserved echogenic hilum, no calcification; CT — homogeneous, enhancing unilateral cervical nodes (levels II–V); ¹⁸F-FDG PET/CT — multiple hypermetabolic nodes that can strongly mimic lymphoma (PMID 37383134).
• Differential diagnosis (critical): non-Hodgkin lymphoma and Hodgkin lymphoma (most important to exclude), SLE lymphadenitis (histologically indistinguishable in ~20% — look for hematoxylin bodies, abundant plasma cells, DNA deposits), tuberculosis and other granulomatous infections, cat-scratch disease, infectious mononucleosis, HSV lymphadenitis, Sweet syndrome, histoplasmosis, syphilis, leprosy (PMC11592699).
• Genetic/omics testing: not indicated clinically — HLA typing is a research tool, not diagnostic. No newborn/carrier/cascade screening applies.

11. Outcome / Prognosis

• Overall prognosis: excellent — most patients recover spontaneously within months.
• Mortality: ~2.1%, essentially confined to severe cases with hemophagocytic lymphohistiocytosis (HLH)/macrophage-activation syndrome, connective-tissue disease, or complications such as pulmonary hemorrhage, DIC, or heart failure (PMID 37383134).

"With a reported fatality rate of 2.1% and severe and fatal cases having been generally associated with hemophagocytic syndrome or connective tissue disease." — PMID 37383134

• Recurrence: ~3–23% (adults); higher in children.
• Progression to autoimmunity (key prognostic concern): a subset develop SLE — before, concurrent with, or after KFD (reported split ≈ KFD-before 30% / simultaneous 47% / KFD-after 23%). Recurrent KFD is an "intermediate status between transient KFD and overt autoimmune disease," associated with higher ANA positivity (57% vs 7%) and lower C4 (PMID 39961627). Long-term follow-up with ANA monitoring is recommended.
• Prognostic factors: ANA positivity, low complement (C4), extranodal/CNS involvement, HLH, and necrotizing histology (larger nodes, longer course) predict more severe/protracted or recurrent disease.
• Complications: HLH/MAS, aseptic meningitis/meningoencephalitis, cerebellar ataxia, optic neuritis, myocarditis, hepatitis, uveitis — all uncommon.

12. Treatment

No approved disease-specific therapy; management is empirical and largely supportive — the disease self-resolves (PMC11592699; PMID 37383134).

• Pharmacogenomics: none established for KFD.
• Advanced therapeutics (gene/cell/RNA/targeted/immuno): not applicable — no targeted or biologic therapy is standard.
• Surgery: limited to diagnostic excisional biopsy; not therapeutic (MAXO:0000004 surgical procedure).
• Clinical trials: essentially none of note; a historical observational study exists (NCT00172445, "Clinical Studies of Kikuchi's Disease"). No modern interventional RCTs.
• Response: corticosteroids reliably shorten severe episodes; overall outcomes are excellent regardless.

13. Prevention

• Primary prevention: none — cause unknown, so no vaccine or risk-factor modification.
• Secondary prevention / early detection: the practical "prevention" target is early lymph-node biopsy to avoid misdiagnosis as lymphoma and unnecessary chemotherapy, and post-diagnosis surveillance for SLE (periodic ANA/complement).
• Tertiary prevention: monitor and promptly treat recurrences, HLH, and evolving autoimmunity.
• Immunization / public-health / behavioral / prophylaxis / genetic counseling: not applicable (non-heritable, non-communicable).

14. Other Species / Natural Disease

• Taxonomy: KFD is described only in humans (NCBITaxon:9606).
• Natural animal disease: none reported — no recognized veterinary/wildlife counterpart in OMIA or veterinary literature.
• Orthologous genes: the implicated HLA-DP loci belong to the MHC class II system, which has orthologues across mammals, but no cross-species KFD phenotype is documented.
• Zoonotic / cross-species transmission: not applicable (KFD is not an infection).

15. Model Organisms

• Animal models: none validated. There is no established mouse, rat, zebrafish, or other in-vivo model that recapitulates KFD. This is a genuine knowledge gap — appropriate for a KNOWLEDGE_GAP discussion node in the KB entry.
• In-vitro / ex-vivo systems: mechanistic work relies on human lymph-node tissue (IHC, in-situ apoptosis assays, interferon-marker studies) rather than engineered models.
• Implication for curation: all mechanistic evidence should be tagged HUMAN_CLINICAL or IN_VITRO (tissue-based); do not tag any KFD evidence as MODEL_ORGANISM, since no animal model data exist.

Curation Summary — high-confidence anchors for the KB entry

• Identity: MONDO:0018864 / ORPHA:50918 / MeSH D020042; synonym "histiocytic necrotizing lymphadenitis."
• Core pathophysiology edge chain: viral/antigen trigger → type I interferon activation + pDC recruitment → exaggerated CD8⁺ cytotoxic T-cell response → Fas–FasL apoptosis (karyorrhexis) → histiocytic phagocytosis/necrosis (no neutrophils, no granulomas) → self-limited resolution.
• Genetics: HLA-DPA1*01 / HLA-DPB1*0202 susceptibility (association only).
• Phenotype core: cervical lymphadenopathy (HP:0002716/HP:0002726) + fever (HP:0001945) + leukopenia (HP:0001882) + elevated ESR (HP:0003565) + elevated LDH (HP:0025435).
• Prognosis: self-limited, ~2.1% mortality (via HLH/CTD); recurrence 3–23%; SLE overlap is the defining long-term concern.
• Treatment: NSAIDs → corticosteroids → hydroxychloroquine/IVIG; supportive.

Priority PMIDs to fetch & snippet-validate before committing

• PMID 37383134 — Kikuchi-Fujimoto disease: a comprehensive review (interferon mechanism, Fas-FasL, 2.1% mortality, imaging).
• PMID 39961627 — clinicopathological features & recurrence risk factors (subtype %, recurrence 23%, ANA/C4).
• PMID 19141377 — immature dendritic-cell phenotype of lesional cells (CD123, CD303, MPO, MxA, fascin-neg).
• Archives of Pathology & Lab Medicine 2018;142(11):1341 (Perry & Choi) — authoritative pathology review.
• MDPI Diseases 2024 case series (PMC11592699) and the HLA familial case (PMC10803893).

⚠️ Follow the dismech SOP: run just fetch-reference PMID:37383134 (etc.), then confirm each snippet: is an exact substring of the cached abstract before validating — several quotes above are paraphrase-adjacent and must be tightened to verbatim abstract text. Re-verify the MONDO/ICD-11 mappings against the local ontology adapter per the NEC preflight.

Sources: - Kikuchi-Fujimoto disease: A comprehensive review — PMID 37383134 / PMC10294163 - Kikuchi–Fujimoto Disease: A Case Series and Review — PMC11592699 (MDPI Diseases 2024) - Clinicopathological features and risk factors for recurrence — PMID 39961627 / PMC12129606 (Histopathology 2025) - Retrospective study of 134 cervical KFD patients — PMC10446312 - Lesional cells exhibit an immature dendritic cell phenotype — PMID 19141377 - KFD in HLA partially-matched siblings (familial susceptibility) — PMC10803893 - Genes associated with KFD via RNA/exome sequencing — ScienceDirect 2021 - SARS-CoV-2 triggering KFD — PMC10077921 - KFD + SLE + HLH case report — PMC6551871 - Kikuchi-Fujimoto Disease: A Review — Arch Pathol Lab Med 2018 - Orphanet ORPHA:50918 · NORD MONDO listing · GARD 6834 - StatPearls: Kikuchi-Fujimoto Disease — NBK430830